EBR:UCB - BE0003739530 - Common Stock
The current stock price of UCB.BR is 206.9 EUR. In the past month the price increased by 12.14%. In the past year, price increased by 28.99%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY.DE | ELI LILLY & CO | 44.84 | 588.70B | ||
1LLY.MI | ELI LILLY & CO | 44.78 | 587.85B | ||
ZEG.DE | ASTRAZENECA PLC | 18.4 | 432.52B | ||
JNJ.DE | JOHNSON & JOHNSON | 17.77 | 367.61B | ||
RHO.DE | ROCHE HOLDING AG-BR | 14.74 | 250.06B | ||
NOT.DE | NOVARTIS AG-REG | 14.78 | 214.61B | ||
NOV.DE | NOVO NORDISK A/S-B | 14.08 | 209.02B | ||
SAN.PA | SANOFI | 10.53 | 193.90B | ||
SNW.DE | SANOFI | 10.53 | 193.90B | ||
1SAN.MI | SANOFI | 10.52 | 193.75B | ||
1MRKX.MI | MERCK & CO. INC. | 11.06 | 182.59B | ||
6MK.DE | MERCK & CO. INC. | 10.91 | 180.09B |
UCB SA engages in the research and development of biopharmaceuticals products. The company is headquartered in Anderlecht, Bruxelles-Capitale and currently employs 9,378 full-time employees. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.
UCB SA
Allee de la Recherche, 60
Anderlecht BRUXELLES-CAPITALE BE
Employees: 9215
Phone: 3225599999
The current stock price of UCB.BR is 206.9 EUR. The price increased by 1.12% in the last trading session.
The exchange symbol of UCB SA is UCB and it is listed on the Euronext Brussels exchange.
UCB.BR stock is listed on the Euronext Brussels exchange.
25 analysts have analysed UCB.BR and the average price target is 224.8 EUR. This implies a price increase of 8.65% is expected in the next year compared to the current price of 206.9. Check the UCB SA stock analysts ratings, price target forecast and up-and down grades for more detailed information.
UCB SA (UCB.BR) has a market capitalization of 40.24B EUR. This makes UCB.BR a Large Cap stock.
UCB SA (UCB.BR) currently has 9215 employees.
UCB SA (UCB.BR) has a support level at 201.26. Check the full technical report for a detailed analysis of UCB.BR support and resistance levels.
The Revenue of UCB SA (UCB.BR) is expected to grow by 18.48% in the next year. Check the estimates tab for more information on the UCB.BR EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
UCB SA (UCB.BR) has a dividend yield of 0.48%. The yearly dividend amount is currently 1.36. Check the full fundamental report for a detailed analysis of UCB.BR dividend history, reliability and sustainability.
UCB SA (UCB.BR) will report earnings on 2026-02-25, after the market close.
The PE ratio for UCB SA (UCB.BR) is 32.23. This is based on the reported non-GAAP earnings per share of 6.42 and the current share price of 206.9 EUR. Check the full fundamental report for a full analysis of the valuation metrics for UCB.BR.
ChartMill assigns a technical rating of 10 / 10 to UCB.BR. When comparing the yearly performance of all stocks, UCB.BR is one of the better performing stocks in the market, outperforming 89.3% of all stocks.
ChartMill assigns a fundamental rating of 6 / 10 to UCB.BR. UCB.BR has an average financial health and profitability rating.
Over the last trailing twelve months UCB.BR reported a non-GAAP Earnings per Share(EPS) of 6.42. The EPS increased by 75.41% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 19.45% | ||
ROA | 7.75% | ||
ROE | 13.76% | ||
Debt/Equity | 0.29 |
25 analysts have analysed UCB.BR and the average price target is 224.8 EUR. This implies a price increase of 8.65% is expected in the next year compared to the current price of 206.9.
For the next year, analysts expect an EPS growth of 50.88% and a revenue growth 18.48% for UCB.BR